Helical

Helical develops a virtual AI lab for drug discovery that turns biological data into frontier discovery systems using bio foundation models tuned to specific biology. The platform enables target ID and biomarker discovery by aligning bio foundation models to experimental data at scale, orchestrating models into ranked candidate shortlists with mechanistic grounding, and therapeutically relevant benchmarking that scores every harness, model, and candidate. Helical's benchmark demonstrates 4x improvement over DESeq2 baselines for target identification across seven indications. The platform compounds wet-lab results and scientist decisions into a persistent edge that improves with every experiment. Founded in 2024 and headquartered in Luxembourg, the company has raised approximately $10M in seed funding. Helical differentiates itself through its sovereign lab approach with no data lock-in or model provider data leakage, SOC 2 Type II compliance in progress, deployed science engineers partnering with client teams, and adoption by top-20 pharma R&D organizations under NDA.